# Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

> **NCT03080974** · PHASE2 · RECRUITING · sponsor: **University of Louisville** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab
- **PROCEDURE:** Irreversible Electroporation

## Key facts

- **NCT ID:** NCT03080974
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-08-14
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080974, "Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03080974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*